CLINICAL_TRIALS ClinicalTrials.gov record update

Single-arm Open-label Phase I/II Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06607692
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:55.541179+00:00
Published At: 2026-04-14T00:00:00+00:00
Record Updated At: 2026-04-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Solid Tumor Cancer", "Medulloblastoma", "High Risk Neuroblastoma", "High Grade Gliomas", "Meningioma", "Paraganglioma", "Pheochromocytoma", "Neuroendocrine Tumours (NET)", "Adrenal Tumours", "DIPG", "Glioblastoma", "Glioblastoma (GBM)", "Osteosarcoma Recurrent", "Carcinoma Adrenal", "Synovial Sarcomas", "Esthesioneuroblastoma", "Neuroblastoma Recurrent", "Solid Tumor Refractory to Conventional Treatment", "Medulloblastoma Recurrent", "Paraganglioma/ Phaeochromocytoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-14"
protocolSection.identificationModule.nctId: "NCT06607692"
protocolSection.identificationModule.officialTitle: "Single-arm Open-label Phase I/II Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera\u00ae) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed)."
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.